Latest News for: glucagon

Edit

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple ...

Nasdaq Globe Newswire 24 Mar 2025
(United Biotechnology), have entered into an exclusive license agreement for UBT251, a triple agonist ...
Edit

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist

Vietnam News 24 Mar 2025
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist ... The addition of a candidate targeting glucagon, as well as GLP-1 ...
Edit

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate ...

Nasdaq Globe Newswire 17 Mar 2025
... into the clinic the first oral dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment for patients with obesity, metabolic and fibrotic disorders.
Edit

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders (Form 8-K) (Entera Bio Ltd)

Public Technologies 17 Mar 2025
) OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders ... Currently, there are no approved dual GLP-1/Glucagon agonists available.
  • 1
×